Salute e Benessere

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 24 June 2024– On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the…
Nasdaq GlobeNewswire
24/06/2024

Buyback of Class B shares in Essity during week 25, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
24/06/2024

Sun Pharma Completes Taro Merger

Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, said, "We are pleased with the successful completion of Taro merger process. This milestone marks a significant step forward for both organizations, allowing us to effectively leverage each other's strengths and capabilities. Together, we are excited about starting this new chapter and creating a more robust, successful future for the combined entity." Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, said…
PR Newswire
24/06/2024

TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the…

TOFIDENCE™ complements existing portfolio of immunology biosimilars commercialized by BiogenCambridge, Mass., June24, 2024(GLOBE NEWSWIRE) -- BiogenInc. (Nasdaq: BIIB) announced that the European Commission (EC) has granted approval for TOFIDENCE TM, a biosimilar monoclonal antibody referencing ROACTEMRA ®1. The intravenous formulation of TOFIDENCE has been granted marketing authorization by the EC for the treatment of moderate to severe active rheumatoid arthritis,...
Nasdaq GlobeNewswire
24/06/2024

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt…

Pelareorep combination therapy advancing towards registration-enabling study in pancreatic cancer Pelareorep combination therapy advancing towards registration-enabling study in pancreatic cancer SAN DIEGOandCALGARY, AB,June 24, 2024/PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced thatMatt Coffey, PhD, President and Chief Executive Officer of Oncolytics will...
PR Newswire
24/06/2024

BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug…

Designation is based onpre-clinical data and data from an ongoing Phase 1/2 trial for BNT324/DB-1311, with antitumor activity and a manageable safety profile demonstrated by preliminary Phase 1/2 clinical datafrom patients with advanced or metastatic solid tumors1, 2With the Fast Track designation,the development of BNT324/DB-1311 can benefit from more frequent engagement with the U.S. Food and Drug Administration (“FDA”) to support development and expedite regulatory review...
Nasdaq GlobeNewswire
24/06/2024

Vitamin K2 Market worth $265 million by 2029 - Exclusive Report by…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=80962397 Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=80962397 Browse in-depth TOC on "Vitamin K2 Market" 80 – Tables 40 – Figures200 – Pages Market growth for Vitamin K2 has been further facilitated by increasing consumer awareness and preference for health and wellness products. As populations age, there is a growing awareness and concern about maintaining...
PR Newswire
24/06/2024

Wingderm® Shines at IMCAS Asia 2024 with the Innovative Aesthetic Solutions

Throughout the exhibition, Derma Innovation, Wingderm®'s distributor in Thailand, has provided substantial support and assistance. With the local advantages of Derma Innovation, Wingderm® can communicate with visitors more effectively, enhancing their trust and recognition of Wingderm®'s products and services. Throughout the exhibition, Derma Innovation, Wingderm®'s distributor inThailand, has provided substantial support and assistance. With the local advantages of Derma Innovation,...
PR Newswire
24/06/2024

First gene therapy for prevalent pathologies in neurology receives FDA IND…

EG110A to start Phase 1b/2a clinical study in Neurogenic Detrusor Overactivity (NDO) patients NDO is a severe bladder condition affecting millions of patients living with Spinal Cord Injury, Multiple Sclerosis, Parkinson's disease and other neurological disordersOther severe pathologies of the bladder to be investigated following this studyPreclinical data show EG110A's potential for long-lasting efficacy on urinary continence and to address shortcomings of existing therapiesOpens...
Nasdaq GlobeNewswire
24/06/2024

COSRX Hero Products Awarded "Amazon Choice" Badges As UK Shoppers Demand for…

Amazon's Choice is a coveted accolade awarded to products that have received high ratings, are well-priced, and are available to ship immediately. This endorsement not only signifies superior quality and customer satisfaction but also highlights the product's reliability and the positive experiences of numerous users. Amazon's Choice is a coveted accolade awarded to products that have received high ratings, are well-priced, and are available to ship immediately. This endorsement not only...
PR Newswire
24/06/2024

PolTREG's type-1 diabetes Treg cell therapy PTG-007 demonstrates long-term…

PTG-007 administration resulted in improved remission and insulin secretion Patients monitored for up to 12 yearsPlanned pivotal Phase 2/3 study is final step for PolTREG to bring PTG-007 to market Gdańsk, Poland – 24 June 2024– PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces that its polyclonal Treg cell therapy PTG-007 demonstrated...
Nasdaq GlobeNewswire
24/06/2024

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the…

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies NANTES, France, June 24, 2024 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced that the Company has entered into a commercial and revenue sharing agreement with leading global cancer center.This exclusive and worldwide agreement with Memorial Sloan Kettering Cancer Center (MSK) covers OSE Immunotherapeutics' patent rights and jointly...
Nasdaq GlobeNewswire
24/06/2024

Roche launches new analytical units for cobas® pro integrated solutions…

The cobas® c 703 and cobas® ISE neo analytical units, deliver higher testing capacity and increased automation helping to improve laboratory workflows and advance patient care.The new cobas c 703 analytical unit offers industry-leading high throughput clinical chemistry testing 1with up to 2,000 tests per hour and 70 reagent positions, doubling the existing clinical chemistry throughput on cobas pro integrated solutions.The new cobas ISE neo analytical unit delivers more...
Nasdaq GlobeNewswire
24/06/2024

Valneva Announces Health Canada Approval of the World's First Chikungunya…

Saint-Herblain (France), June 24, 2024–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has approved IXCHIQ ®, Valneva's single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. This decision marks the second approval the Company has received for IXCHIQ ®following approval from the U.S. Food and Drug Administration (FDA) in November 2023. The European...
Nasdaq GlobeNewswire
24/06/2024

AstriVax enters clinical phase with its novel vaccine platform technology

The first participants have been dosed in SAFYR, a Phase I clinical trial to test the safety and efficacy of two prophylactic vaccines developed with AstriVax technology. The study will also provide clinical proof of concept for the company's platform technology. Following these first-in-human data, AstriVax plans to advance its immunotherapies for chronic Hepatitis B to clinical development. Leuven - June 24, 2024- The first participants have been dosed in a Phase I clinical...
Nasdaq GlobeNewswire
24/06/2024

Juniper Biologics Expands Distribution Rights for Caris Life Sciences' Molecular…

Juniper Biologics is committed to driving positive change in the pharmaceutical industry on a global scale. Aligned with its mission to deliver transformative therapies through bold scientific innovation, Juniper's collaboration with Caris will enhance access to quality treatments for patient communities in the Middle East and Africa. Juniper continues to pursue impactful partnerships aimed at uplifting communities and individuals, especially in underserved regions where access to advanced…
PR Newswire
24/06/2024

Ascentage Pharma Announces Confidential Submission of Draft Registration…

Logo - https://mma.prnewswire.com/media/891219/Ascentage_Pharma_Logo.jpg Logo -https://mma.prnewswire.com/media/891219/Ascentage_Pharma_Logo.jpg View original content: https://www.prnewswire.co.uk/news-releases/ascentage-pharma-announces-confidential-submission-of-draft-registration-statement-for-proposed-initial-public-offering-of-american-depositary-shares-302179764.html
PR Newswire
24/06/2024

DUREX GLOBAL SEX SURVEY REVEALS GREATER SEXUAL SATISFACTION

The 2024 data has unveiled that levels of sexual satisfaction have increased across the world, as 57% of sexually active people stated they are emotionally satisfied and 56% said they were physically satisfied, up 12% and 21%, respectively, since 2006 The 2024 data has unveiled that levels of sexual satisfaction have increased across the world, as 57% of sexually active people stated they are emotionally satisfied and 56% said they were physically satisfied, up 12% and 21%, respectively…
PR Newswire
24/06/2024

KFSHRC Successfully Produces the First Therapeutic T-Cells in the Kingdom

Treatment Costs Reduced by around 80% and Accelerated Access to Treatment RIYADH, Saudi Arabia, June23, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) has successfully produced CAR T-cells internally for cancer treatment. This breakthrough has reduced the cost of treatment from 1.3 million SAR to approximately 250,000 SAR per treatment, making it available to patients within 14 days. This achievement overcomes all cost and shipping challenges,...
Nasdaq GlobeNewswire
23/06/2024

Juniper Biologics Expands Distribution Rights for Caris Life Sciences' Molecular…

Juniper Biologics is committed to driving positive change in the pharmaceutical industry on a global scale. Aligned with its mission to deliver transformative therapies through bold scientific innovation, Juniper's collaboration with Caris will enhance access to quality treatments for patient communities in the Middle East and Africa. Juniper continues to pursue impactful partnerships aimed at uplifting communities and individuals, especially in underserved regions where access to advanced…
PR Newswire
23/06/2024

Hisense Enhances UEFA EURO 2024™ Excitement with Immersive Fan Zones

Crafting a scenario-based experience for Hisense's home appliances, Hisense has set up Hisense Fan Zones in Berlin and Munich. These zones feature product displays and interactive games including the Hisense Training Lab, Goalpost Defense, Samba Dance Steps, and Table Football. These fan activities further embody Hisense's determination to 'Never Settle for No.2 Globally'. Crafting a scenario-based experience for Hisense's home appliances, Hisense has set up Hisense Fan Zones…
PR Newswire
23/06/2024

Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and…

The study results demonstrated a superior efficacy of GZR18 Injection than placebo for weight reduction in Chinese obese subjects. After 35 weeks of treatment, the mean weight change from baseline in the GZR18 QW group was -16.5 kg (95% CI: -19.9 kg, -13.1 kg); the placebo-adjusted mean percent weight change from baseline was -18.6% (95% CI: -25.5%, -11.6%). Although it was not a head-to-head study, when compared to the published data on weight reduction of similar products currently available…
PR Newswire
22/06/2024

Casino Group: Agreement with Rocca and Auchan Retail France for the sale of…

Casino Group has signed an agreement with Rocca and Auchan Retail France for the sale of its subsidiary Codim 2 Paris, 22 June 2024Casino Group announces today that it has signed a unilateral purchase agreement for the sale of Codim 2, which operates 4 hypermarkets, 9 supermarkets, 3 cash & carries and 2 drive-throughs in Corsica, with sales of 332 million euros excluding taxes in 2023.As part of the sale, Rocca Group has undertaken to take over all the stores, which will be...
Nasdaq GlobeNewswire
22/06/2024

Description of the Share Repurchase Program Authorised by the Ordinary General…

Pursuant to Article 241-2 of the AMF General Regulations ( Règlement Général de l'Autorité des marchés financiers ), the purpose of this description is to present the objectives and terms of the Company's share repurchase program approved by the Ordinary General Meeting of 20 June 2024, it being specified that the Company does not to date intend to pursue any objective other than to animate the market under a liquidity agreement which has been in place since the listing on Euronext...
Nasdaq GlobeNewswire
21/06/2024
Altri  Comunicati